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Non-ESBL Klebsiella antibiogram in Muller Hinton agar plate 
 
- Organism sensitive to Beta Lactam Antibiotics 
 
ESBL Klebsiella antibiogram in Muller Hinton agar plate 
 
 
Organism was resistant to Cefotaxime and Ceftazidime, but has 
intermediate sensitivity to Amikacin 
 
Amikacin 
Ciprofloxacin
Cefotaxime
Ceftazidime 
Gentamycin 
Cefotaxime 
Nitrofurantoin
Ampicillin
Gentamycin
Ciprofloxacin
Cotrimoxazole
Ceftazidime
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Biochemical reactions for the identification of Klebsiella pneumoniae 
 
Biochemical reactions for the identification of Klebsiella oxytoca 
 
TSI : A/A G+ INDOLE : NEGATIVE 
METHY RED : NEGATIVE VOGES PROSKAUER TEST : POSITIVE 
CITRATE : UTILIZED UREASE : POSITIVE 
SUGARS – Glucose, Lactose, Sucrose, Maltose and Mannitol fermented. 
TSI : A/A G+ INDOLE : POSITIVE 
METHY RED : NEGATIVE VOGES PROSKAUER TEST : POSITIVE 
CITRATE : UTILIZED UREASE : POSITIVE 
SUGARS – Glucose, Lactose, Sucrose, Maltose and Mannitol fermented. 
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INTRODUCTION 
Klebsiella is well known to most clinicians as a cause of 
community-acquired bacterial pneumonia, occurring particularly in 
chronic alcoholics, which has a high fatality rate if untreated. The 
vast majority of Klebsiella infections, however, are associated with 
hospitalization. As opportunistic pathogens, Klebsiella species 
primarily attack immunocompromised individuals who are 
hospitalized and suffer from severe underlying diseases such as 
diabetes mellitus or chronic pulmonary obstruction. It is estimated 
that Klebsiella species cause 8% of all nosocomial bacterial 
infections in the United States and in Europe. No great 
geographical variations frequency has been noted. In the United 
States, Klebsiella accounts for 3 to 7% of all nosocomial bacterial 
infections, placing them among the eight most important infectious 
pathogens in hospitals, and data collected from the United 
Kingdom, Italy22 and from Germany are remarkably similar to those 
reported by the Centers for Disease Control and Prevention.50 
 
The urinary tract is the most common site of infection. 
Klebsiella accounts for 6 to 17% of all nosocomial urinary tract 
infections (UTI). As a cause of nosocomial gram-negative 
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bacteremia, Klebsiella is second only to Escherichia coli. Klebsiella 
species are often the pathogens involved in neonatal sepsis.  
 
Added to this, due to the extensive spread of antibiotic-
resistant strains, especially of extended-spectrum β-lactamase 
(ESBL) producing strains, there has been renewed interest in 
Klebsiella infections. Even hospital personnel have elevated rates 
of Klebsiella carriage. The high rate of nosocomial Klebsiella 
colonization appears to be associated with the use of antibiotics 
rather than with factors connected with delivery of care in the 
hospital. 
Since 1982, strains that produce ESBL’s, which render them 
resistant to extended-spectrum Cephalosporins, have evolved. 
The hallmark of these strains, resistance to ceftazidime, is 
observed in both Klebsiella pneumoniae and Klebsiella oxytoca 
isolates. ESBL’s are usually plasmid mediated. Since these 
plasmids are easily transmitted among different members of the 
Enterobacteriaceae, accumulation of resistance genes results in 
strains that contain multiresistant plasmids. For this reason, ESBL 
producing isolates are resistant to a variety of classes of 
antibiotics. Moreover, the emergence of these multiple resistant 
Klebsiella strains is unfortunately accompanied by a relatively high 
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stability of the plasmids encoding ESBL’s. Even years after 
discontinuation of ceftazidime and other extended-spectrum 
Cephalosporins, continued colonization of patients by ESBL 
producing Klebsiella strains has been observed. Since ESBL 
production frequently is accompanied by multiresistance to 
antibiotics, therapeutic options become limited. 
   
ESBL-producing Klebsiella strains are susceptible to 
Carbapenems such as Imipenem or Meropenem. Both antibiotics 
are the drugs of choice in the treatment of infections due to ESBL-
producing organisms. In this respect, a recent observation is very 
disturbing. For the first time, ESBL producing Klebsiella 
pneumoniae strains, which showed an additional resistance to 
imipenem, have been isolated. These strains possessed a 
transmissible plasmid-mediated AmpC-type β-lactamase. 50 
 
At the same time, these ESBL’s are susceptible to drugs of 
other classes, thereby providing means for timely intervention and 
successful outcome of the patient. Moreover, in Coimbatore, India 
40% of isolates were found to be ESBL producers8, 68% in Delhi 52 
and 87% in Chennai57. Indian studies thus gives a higher 
percentage of ESBL presence compared to international 
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incidence, which all the more makes this study necessary and 
imminent for the current scenario. 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
♦ To isolate and speciate Klebsiella obtained from various 
clinical specimen in the department of Microbiology of 
Government Stanley Hospital.  
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♦  To find out the incidence of ESBL producers amongst 
Klebsiella species. 
♦ To assess the antibiotic sensitivity pattern of ESBL producing 
bacteria in comparison with non-ESBL producers. 
♦ To formulate a treatment plan in ESBL harboring patients 
resistant to routine antibiotics, for effective recovery and  for 
avoiding further emergence and spread of Extended 
Spectrum  β- Lactamases. 
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Review of Literature 
Introduction  
The Enterobacteriaceae are a large, heterogeneous group of 
gram-negative bacilli whose natural habitat is the intestinal tract of 
humans and animals. So they are also called the coliforms and are 
the most common group of gram-negative rods cultured in the 
clinical laboratory and along with staphylococci and streptococci 
are among the most common bacteria that cause disease. The 
term “Enterobacteriaceae” was first proposed by Rahn in 1937, 
and it comprises of organisms that share the following properties. 
They are gram negative bacilli; do not form spores; are motile by 
peritrichate flagella or non-motile; grow on peptone or meat extract 
media without the addition of sodium chloride or other 
supplements; grow well on MacConkey agar; grow both aerobically 
and anaerobically; are active biochemically; Presently, 31 genera 
and 139 species, biogroups and unnamed enteric groups have 
been defined. The Enterobacteriaceae consists of seven tribes, of 
which Klebsielleae forms the fifth tribe. The other members of this 
tribe are the genus Enterobacter, Hafnia, Serratia and Pantoea. 37 
Klebsiella species causes various diseases as given in Table 
below. 
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Hospital-acquired bacterial infections caused by Klebsiella 
spp. 50 
Infection 
% of infections 
caused by 
Klebsiella 
Rank 
UTI                6–17 5–7 
Pneumonia 7–14 2–4 
Septicemia 4–15 3–8 
Wound infections  2–4 6–11 
Nosocomial 
infections  4–17 4–9 
Neonatal 
septicemia  3–20 2–8 
History 
The genus Klebsiella, initially in 1886 called the “Hyalococcus 
pneumoniae” 60 was named after Edwin Klebs, a late 19th Century 
German Microbiologist. The bacillus was also described by Carl 
Friedländer in 1882, and so was also called as the Friedländer’s 
Bacillus. In the past, the name Klebsiella aerogenes was used for 
the non-motile, capsulate, gas producing strains commonly found 
in human faeces and in water. These were similar to strains 
described in the 19th Century as the “Bakterium lactis aerogenes”, 
referred to later as the “Bacterium aerogenes”, and subsequently 
transferred to the genus Klebsiella. This term Bacterium 
aerogenes (later Aerobacter aerogenes), was used by water 
microbiologists to describe a motile strain, presently the 
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Enterobacter species. To avoid the resultant confusion the species 
pneumoniae was brought in vogue.27  
 
Morphology & Cultural characteristics 
Klebsiella are straight, short and thick rods, 0.3 – 1 µm in diameter 
and 0.6 – 6.0 µm in length, arranged singly, in pairs, or in short 
chains. Bacilli are capsulated, gram negative, non-motile, 
facultatively anaerobic chemo-organotropic, having both 
respiratory and fermentative type of metabolism. 10 
In media rich in carbohydrates, the growth on agar is 
luxuriant, grayish white and extremely mucoid. Optimal 
temperature is 37°C (range 12 – 43 °C). In MacConkey agar, they 
form Pink colonies due to Lactose fermentation. D-Glucose and 
other carbohydrates are catabolized with the production of acid 
and gas. There is no haemolysis of horse or sheep red cells. 27 
Epidemiology & Habitat 
Klebsiella species are ubiquitous in nature. In humans, K. 
pneumoniae is present as a saprophyte in the nasopharynx and in 
the intestinal tract. The detection rate in stool samples ranges from 
5 to 38%, while rates in the nasopharynx range from 1 to 6%. 
Because gram-negative bacteria do not find good growth 
conditions on the human skin, Klebsiella species are rarely found 
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there and are regarded simply as transient members of the flora. 
These carrier rates change drastically in the hospital environment, 
where colonization rates increase in direct proportion to the length 
of stay. Even hospital personnel have elevated rates of Klebsiella 
carriage. Reported carrier rates in hospitalized patients are 77% in 
the stool, 19% in the pharynx, and 42% on the hands of patients. 
The high rate of nosocomial Klebsiella colonization appears to be 
associated with the use of antibiotics rather than with factors 
connected with delivery of care in the hospital. Furthermore, 
widespread use of antimicrobial therapy has often been held 
responsible for the occurrence of multiple resistant Klebsiella 
strains in hospitals. In the 1970s, the strains were chiefly 
aminoglycoside-resistant Klebsiella strains. Since 1982, strains 
that produce ESBL’s, which render them resistant to extended-
spectrum cephalosporins, have evolved. In Europe, the β-
lactamases of ceftazidime-resistant Klebsiella strains are 
commonly of the SHV-5 type, whereas TEM-10 and TEM-12 are 
more prevalent in the United States.50 In India, the high prevalence 
of ESBL producing Klebsiella species is reported varying from 6 to 
87.0 per cent. 3 In Tamilnadu, prevalence varies from 20 to 87 
percent. 48 Worldwide the percentage varies from 1.5 to 45 %.10 
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Classification: 50 
Earlier Classification by: 
Cowan Bascomb Ørskov 
K. aerogenes K. aerogenes / oxytoca  K. pneumoniae 
K. edwardsii Edwardsii subsp. pneumoniae 
subsp. edwardsii K. pneumoniae subsp. ozaenae 
subsp. atlantae sensu stricto 
subsp. 
rhinoscleromatis 
K. pneumoniae sensu lato K. oxytoca 
K. ozaenae K. ozaenae K. terrigena 
K. rhinoscleromatis K. planticola (syn. 
K. “unnamed group” K. trevisanii) 
K. 
rhinoscleromatis 
Enterobacter aerogenes K. ornithinolytica 
 
In 2001, Drancourt and colleagues performed a comparative analysis of the 
sequences of the 16S rRNA and rpoB genes (encoding the bacterial RNA 
polymerase β-subunit) of the type strains of nine Klebsiella species, based on 
which they classified Klebsiella into three clusters37 
Cluster I: comprises     (i)   Klebsiella pneumoniae  
subspecies (a) pneumoniae,  
                   (b) rhinoscleromatis and  
                   (c) ozaenae 
     (ii) Klebsiella granulomatis 
 
Cluster II:   comprises Klebsiella ornithinolytica, 
         planticola, 
         trevisanii and 
         terrigena 
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Cluster III: comprises of Klebsiella oxytoca 
Later, based on this classification, the genus Klebsiella was 
divided into two genera, Klebsiella and Raoultella (named after the 
French bacteriologist Didier Raoult) and Klebsiella oxytoca was left 
as a monomorphic taxon. Therefore, 
Cluster I consists of Klebsiella and  
Cluster II consists of Raoutella. 
Further, Granier et al have further divided Klebsiella taxon into two 
clades, corresponding to two genetic groups, called oxy-1 and oxy-
2. 37 
Biotyping 37 
Klebsiella 
pneumoniae 
(%) 
Raoultella 
(Klebsiella) (%)
  
Klebsiell
a 
oxytoca 
(%) 
oz
ae
na
e 
pn
eu
m
on
ia
e 
rh
in
os
cl
er
o
m
at
is
 
or
ni
th
in
ol
yt
i
ca
 
pl
an
tic
ol
a 
te
rr
ig
en
a 
1.  Indole Test 99 0 0 0 100 20 0 
2.  Methyl Red 20 98 10 100 96 100 60 
3.  Voges Proskauer Test 95 0 98 0 70 98 100
4.  Citrate (Simmons) 95 30 98 0 100 100 40 
5.  Urea Hydrolysis 90 10 95 0 100 98 0 
6.  Lysine Decarboxylase 99 40 98 0 100 100 100
7.  Arginine Dihydrolase 0 6 0 0 0 0 0 
8.  Ornithine 
Decarboxylase 0 3 0 0 100 0 20 
9.  Motility 0 0 0 0 0 0 0 
10. D-Glucose Acid 100 100 100 100 100 100 100
11. D-Glucose Gas 97 50 97 0 100 100 80 
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12. Lactose Fermentation 100 30 98 0 100 100 100
13. Sucrose Fermentation 0 0 0 0 0 0 0 
14. Maltose Fermentation 100 95 98 100 100 100 100
15. D-Mannitol 
Fermentation 99 100 99 100 100 100 100
16. D-Mannose 
Fermentation 100 100 99 100 100 100 100
17. Nitrate Nitrite 100 80 99 100 100 100 100
18. Oxidase, Kovac’s 0 0 0 0 0 0 0 
19. ONPG 100 80 99 0 100 100 100
Serotyping50 
It is based mainly on a division according to the capsule antigens. 
Of 82 capsule antigens described, 77 types form the basis for an 
internationally recognized capsule antigen scheme. 12 different O-
antigen types of Klebsiella have also been described.  
Molecular typing methods50 
Molecular typing methods, as applied to the genus Klebsiella, are 
still in their infancy. Preliminary descriptions have been presented 
on plasmid profiles, ribotypes, multilocus enzyme analyses, and 
applications of pulsed-field gel electrophoresis.  
 
Pathogenesis50 
(i) Capsular Antigens  
klebsiellae usually develop prominent capsules composed of 
complex acidic polysaccharides, which can be classified into 77 
serological types. Capsules are essential to the virulence of 
Klebsiella. This protects the bacterium from phagocytosis by 
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polymorphonuclear granulocytes. Strains expressing capsule types 
K1 and K2 are considered especially likely to be virulent.  
(ii) Pili (Fimbriae) 50 
Pili (otherwise known as fimbriae) are non-flagellar, filamentous 
projections on the bacterial surface, helping in attachment to their 
host. These structures are up to 10 mm long and have a diameter 
of 1 to 11 nm. There are two predominant types in Klebsiella spp. 
 
(a) Type 1 (common) pili. They are Mannose sensitive 
Haemagglutinins (MSHA). These pili bind to mucus or to epithelial 
cells of the urogenital, respiratory, and intestinal tracts.  
(b) Type 3 pili. These are mannose-resistant, Klebsiella-like 
hemagglutination (MR/K-HA). These adhere to endothelial cells, 
epithelia of the respiratory tract, and uroepithelial cells. Three new 
types of Klebsiella adhesins have been recently reported. 
(i) The R-plasmid-encoded CF29K adhesin of Klebsiella 
pneumoniae mediate adherence to the human intestinal cell lines. 
(ii) Another new Klebsiella adhesin characterized by aggregative 
adhesion to intestinal cell lines  
The two adhesins mentioned above are non-fimbrial. 
(iii) A new fimbria KPF-28 is putative colonization factor of the 
human gut. Interestingly, this fimbrial type has been found in the 
- 35 - 
majority of Klebsiella pneumoniae strains producing CAZ-5/SHV-4 
type ESBL.  
(iii) Siderophores50 
Iron is an essential factor in bacterial growth, functioning mainly as 
a redox catalyst in proteins participating in oxygen and electron 
transport processes. Under iron-deficient conditions, e.g., in the 
host milieu, enterobacteria synthesize a variety of siderophores, 
which belong to two different chemical groups, one consisting of 
the phenolate-type siderophores siderophores and one consisting 
of the hydroxamate-type siderophores. 
(iv) Lipopolysaccharides50 
Due to their endotoxic properties, LPS are considered important in 
the pathology of septicemia. The small number of different 
Klebsiella O-types is a great advantage with respect to their 
applicability as vaccines. Only eight O types are known, O1 being 
the most commonly found O type in clinical isolates.  
(v) Capsular Polysaccharides50 
CPS has been the obvious vaccine candidates for several 
reasons. Capsules are produced by almost all Klebsiella strains; 
they represent the outermost layer of surface structures in contact 
with the host milieu, and they have been proven to be highly 
immunogenic and nontoxic.  
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Antibiotic Sensitivity50 
Inherently, klebsiella is sensitive to certain drugs, like β-lactam 
antibiotics, sulphonamides, fluoroquinolones, aminoglycosides, 
chloramphenicol and nitrofurantoin. They are likewise resistant by their 
genetic makeup to erythromycin, roxithromycin, rifampicin, fusidic acid, 
lincosamides, glycopeptides and streptogramins. 
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Natural Sensitivity pattern of klebsiella50
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Klebsiella 
pneumoniae 
R R S-I s s s s R S-I R 
?t 
s s s s s 
Klebsiella 
ozaenae 
R I-R s s s s s R S-I s s s s s s 
Klebsiella 
rhinoscleromatis 
R R s s s s s I s s s s s s s 
Klebsiella 
oxytoca 
R R S-I s s s s R S-I s s s s s s 
Klebsiella 
planticola  
R R s s s s s R S-I s s s s s s 
K. terrigena R I-R s s s s s R S-I s s s s s s 
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Beta Lactam antibiotics:11 
These are antibiotics having a beta-lactam ring26, consisting of 
i) Penicillins 
ii) Cephalosporins 
iii) Monobactams  
iv) Carbapenems 
 
 
 
 
 
Mechanism of action of Beta Lactams 
β-lactam antibiotics, inhibit bacterial growth by interfering with a specific step 
in bacterial cell wall synthesis. The cell wall is composed of a complex 
crosslinked polymer, peptidoglycan consisting of polysaccharides and 
polypeptides. The polysaccharide contains alternating amino sugars, N-
acetylglucosamine and N-acetylmuramic acid. A five-amino-acid peptide is 
linked to the N-acetylmuramic acid sugar. This peptide terminates in D-alanyl-
D-alanine. Penicillin-binding proteins (PBPs) catalyze the transpeptidase 
reaction that removes the terminal alanine to form a crosslink with a nearby 
peptide, which gives cell wall its structural rigidity. Beta-Lactam antibiotics are 
structural analogs of the natural D-Ala-D-Ala substrate and they are covalently 
bound by PBPs at the active site. After a Beta–lactam antibiotic has attached 
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to the PBP, the transpeptidation reaction is inhibited, peptidoglycan synthesis 
is blocked, and the bacterium dies.  
Cephalosporins 
The nucleus of the cephalosporins, 7-aminocephalosporanic acid, 
bears a close resemblance to 6-aminopenicillanic acid. The 
intrinsic antimicrobial activity of natural cephalosporins is low, but 
the attachment of various R1 and R2 groups has yielded drugs of 
good therapeutic activity and low toxicity. First-generation 
compounds have better activity against gram-positive organisms 
and the later compounds exhibit improved activity against gram-
negative aerobic organisms. 
 
Monobactams 
These are drugs with a monocyclic β-lactam ring. They are 
relatively resistant to β-lactamases and active against gram-
negative bacilli. They have no activity against gram-positive 
bacteria or anaerobes. Aztreonam is the only monobactam 
available. It resembles aminoglycosides in its spectrum of activity.  
 
Beta Lactamase Inhibitors35 
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• Clavulanic acid 
• Sulbactam 
• Tazobactam 
These substances resemble β-lactam molecules but by 
themselves have very weak antibacterial action. They are potent 
inhibitors of many but not all bacterial lactamases and can protect 
hydrolyzable penicillins from inactivation by these enzymes. β-
Lactamase inhibitors are most active against Ambler class-A β-
lactamases (plasmid-encoded transposable element [TEM] β - 
lactamases in particular) such as those produced by staphylococci, 
H influenzae, N gonorrhoeae, salmonella, shigella, E coli, and K 
pneumoniae. They are not good inhibitors of class C β-lactamases, 
which typically are chromosomally encoded and inducible, 
produced by enterobacter, citrobacter, serratia, and pseudomonas, 
but they do inhibit chromosomal β-lactamases of legionella, 
bacteroides, and branhamella. 
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Carbapenems 
The carbapenems are structurally related to β-lactam antibiotics. 
They are indicated in infections due to organisms resistant to other 
drugs.33 Ertapenem, imipenem, and meropenem are licensed for 
use in the USA. Imipenem has a wide spectrum with good activity 
against many gram negative bacilli, including Pseudomonas 
aeruginosa, gram-positive organisms, and anaerobes. It is 
resistant to most β-lactamases but not metallo β-lactamases.  
Enterococcus faecium, methicillin-resistant strains of 
staphylococci, Clostridium difficile, Burkholderia cepacia, and 
Stenotrophomonas maltophilia are resistant. Imipenem is 
inactivated by dehydropeptidases in renal tubules, resulting in low 
urinary concentrations. Consequently, it is administered together 
with an inhibitor of renal dehydropeptidase, cilastatin, for clinical 
use. Meropenem is similar to imipenem but has slightly greater 
activity against gram-negative aerobes and slightly less activity 
against gram-positives. It is not significantly degraded by renal 
dehydropeptidase and does not require an inhibitor. Ertapenem is 
less active than meropenem or imipenem against Pseudomonas 
aeruginosa and Acinetobacter species. It is not degraded by renal 
dehydropeptidase. 
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Extended Spectrum Beta Lactamases (ESBL)- 
Definition: ESBLs are β-lactamases capable of conferring 
bacterial resistance to the penicillins, first-, second-, and third-
generation cephalosporins, and aztreonam (but not the 
cephamycins or carbapenems) by hydrolysis of these antibiotics, 
and which are inhibited by β-lactamase inhibitors such as 
clavulanic acid. 18 
 
Evolution of ESBLs19 
Emergence of resistance to β-lactam antibiotics began even before 
the first β-lactam penicillin was developed. The first β-lactamase 
was identified in Escherichia coli prior to the release of penicillin for 
use in medical practice. The first plasmid-mediated β-lactamase in 
gram-negatives, TEM-1, was described in the early 1960s. The 
TEM-1 enzyme was originally found in a single strain of E. coli 
isolated from a blood culture from a patient named Temoniera in 
Greece, hence the designation TEM. Likewise, another common 
plasmid mediated β-lactamase found in Klebsiella pneumoniae 
and E.coli is SHV-1 (for sulphydryl variable). The SHV-1 β-
lactamase is chromosomally encoded in the majority of isolates of 
K. pneumoniae but is usually plasmid mediated in E. coli. Over the 
last 20 years, many new β-lactam antibiotics have been developed 
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that were specifically designed to be resistant to the hydrolytic 
action of β-lactamases. However, with each new class that has 
been used to treat patients, new β-lactamases emerged that 
caused resistance to that class of drug. Not surprisingly, resistance 
to these expanded-spectrum β-lactam antibiotics due to β-
lactamases emerged quickly. This was due to continuous mutation 
of the enzymes. 25 The first of these enzymes capable of 
hydrolyzing the newer β-lactams, SHV-2, was found in a single 
strain of Klebsiella ozaenae isolated in Germany. Because of their 
increased spectrum of activity, especially against the oxyimino-
cephalosporins, these enzymes were called extended-spectrum β-
lactamases (ESBLs). Today, over 57561 different ESBLs have 
been described. 
 
Classification of ESBLs: 
Various classification schemes have been proposed by many 
researchers.  
i) Classification of Sawai et al in 1968 was based on response 
to antisera.  
ii) Richmond and Sykes scheme in 1973 was on the basis of 
substrate profile.  
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iii) Extension of the Richmond and Sykes scheme by Sykes and 
Mathew in 1976 was based on differentiation by isoelectric 
focussing.  
iv) In the scheme proposed by Mitsuhashi and Inoue in 1981, the 
category “cefuroxime hydrolyzing β-lactamases” was added to 
“penicillinase and cephalosporinase” classification.  
v) The groupings proposed by Bush in 1989, was based on 
correlation of substrate and inhibitory properties with molecular 
structure. 
However, the number and variety of enzymes have proliferated 
beyond the boundaries of the scheme.  
vi) A more modern scheme based on molecular structure 
classification was proposed by Ambler includes, of necessity, 
only those enzymes that have been characterized. 
vii) Recently a new classification scheme has been developed to 
integrate functional and molecular characteristics. The Bush-
Jacoby-Medeiros scheme15 puts 178 β-lactamases from 
naturally occurring bacterial isolates into four groups based on 
substrate and inhibitor profiles. 
 
Classification schemes for bacterial b-lactamases15, 36 
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1 1 Ia, Ib, Id CSase C Cephalosporins - - AmpC 
enzymes from 
gram-negative 
bacteria; MIR-
1 
2a 2a Not 
included 
PCase 
V 
A Penicillins + - Penicillinases 
from gram-
positive 
bacteria 
2b 2b III PCase I A Penicillins, 
cephalosporins 
+ - TEM-1, TEM-
2, SHV-1 
2be 2b’ Not 
included 
except 
K1 in 
class IV 
CXase A Penicillins, 
narrow- & 
extended-
spectrum 
cephalosporins, 
monobactams 
+ - TEM-3 to 
TEM-26, SHV-
2 to SHV-6, 
Klebsiella 
oxytoca K1 
2br Not 
inclu
ded 
Not 
included 
Not 
included
A Penicillins +/- - TEM-30 to 
TEM-36, TRC-
1 
2c 2c II, V PCase 
IV 
A Penicillins, 
carbenicillin 
+ - PSE-1, PSE-3, 
PSE-4 
2d 2d V PCase 
II, 
PCase 
III 
D Penicillins, 
cloxacillin 
+/- - OXA-1 to 
OXA-11, PSE-
2 (OXA-10) 
2e 2e Ic CXase A Cephalosporins + - Inducible 
cephalosporin
ases from 
Proteus 
vulgaris 
2f Not 
inclu
ded 
Not 
included 
Not 
included
A Penicillins, 
cephalosporins, 
carbapenems 
+ - NMC-A from 
Enterobacter 
cloacae, Sme-
1 from Serratia 
marcescens 
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3 3 Not 
included 
Not 
included
B Most b-lactams, 
including 
carbapenems 
- + L1 from 
Xanthomonas 
maltophilia, 
CcrA from 
Bac-teroides 
fragilis 
4 4 Not 
included 
Not 
included
NDc Penicillins - ? Penicillinase 
from 
Pseudomonas 
cepacia 
 
a Csase, cephalosporinase; PCase, penicillinase; CXase, cefuroxime-hydrolyzing b-
lactamase. 
b CA, clavulanic acid. 
c ND, not determined. 
 
Detection of ESBLs: 18 
Clinical Laboratory Standards Institute (CLSI) Recommended 
Methods for ESBL Detection: 
I. Screening for ESBL producers-  
(i) Disk diffusion method: 
The CLSI has proposed disk diffusion methods for screening for 
ESBL production by Klebsiellae, Escherichia coli, and Proteus 
mirabilis. Laboratories using disk diffusion methods for antibiotic 
susceptibility testing can screen for ESBL production by noting 
specific zone diameters, which indicate a high level of suspicion for 
ESBL production. Cefpodoxime, ceftazidime, aztreonam, 
cefotaxime, or ceftriaxone is used. However, the use of more than 
one of these agents for screening improves the sensitivity of 
detection. If any of the zone diameters indicate suspicion for ESBL 
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production, phenotypic confirmatory tests should be used to 
ascertain the diagnosis.  
 
II. Phenotypic Confirmatory Tests for ESBL Production 
(i) Cephalosporin/clavulanate combination disks.  
The CLSI advocates use of cefotaxime (30 µg) or ceftazidime 
disks (30 µg) with or without clavulanate (10 µg) for phenotypic 
confirmation of the presence of ESBLs in klebsiellae and 
Escherichia coli. The disk tests are to be performed with confluent 
growth on Mueller- Hinton agar. A difference of 5 mm between the 
zone diameters of either of the cephalosporin disks and their 
respective cephalosporin/clavulanate disk is taken to be 
phenotypic confirmation of ESBL production.  
(ii) Broth microdilution. Phenotypic confirmatory testing can also 
be performed by broth microdilution assays using ceftazidime 
(0.25 to 128 µg/ml), ceftazidime plus clavulanic acid (0.25/4 to 
128/4 µg/ml), cefotaxime (0.25 to 64 µg /ml), and cefotaxime plus 
clavulanic acid (0.25/4 to 64/4 µg/ml). Again it should be 
emphasized that both ceftazidime and cefotaxime should be used. 
A 3-twofold-serial-dilution decrease in MIC of either cephalosporin 
in the presence of clavulanic acid is compared to its MIC when 
tested alone. 
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Quality control when performing screening and phenotypic 
confirmatory tests: Non-ESBL-producing organism (Escherichia 
coli ATCC 25922) and an ESBL-producing organism (Klebsiella 
pneumoniae ATCC 700603) are used as controls. 
Implications of positive phenotypic confirmatory tests: 
According to CLSI guidelines, isolates which have a positive 
phenotypic confirmatory test should be reported as resistant to all 
cephalosporins (except the cephamycins, cefoxitin, and cefotetan) 
and aztreonam, regardless of the MIC of that particular 
cephalosporin. 
III. Commercially Available Methods for ESBL Detection 
(i) Etest for ESBLs. AB Biodisk (Solna, Sweden) produces plastic 
drug-impregnated strips, one end of which contains a gradient of 
ceftazidime (MIC test range 0.5 to 32 µg/ml) and the other with a 
gradient of ceftazidime plus a constant concentration of 
clavulanate (4 µg /ml). The reported sensitivity of the method as a 
phenotypic confirmatory test for ESBLs is 87 to 100% and the 
specificity is 95 to 100%. The manufacturer currently recommends 
a 8-fold reduction in cephalosporin MICs in the presence of 
clavulanate. 
(ii) Vitek ESBL cards. Vitek ESBL test (bioMerieux Vitek, 
Hazelton, Missouri) utilizes cefotaxime and ceftazidime, alone (at 
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0.5 µg/ml), and in combination with clavulanic acid (4 µg/ml). 
Inoculation of the cards is identical to that performed for regular 
Vitek cards. Analysis of all wells is performed automatically once 
the growth control well has reached a set threshold (4 to 15 hours 
of incubation). A predetermined reduction in the growth of the 
cefotaxime or ceftazidime wells containing clavulanic acid, 
compared with the level of growth in the well with the 
cephalosporin alone, indicates a positive result. Sensitivity and 
specificity of the method exceed 90%. 
(iii) MicroScan panels. Dade Behring MicroScan (Sacramento, 
Calif.) produces dehydrated panels for microdilution antibiotic 
susceptibility testing. 
(iv) BD Phoenix Automated Microbiology System. The Phoenix 
ESBL test uses growth response to cefpodoxime, ceftazidime, 
ceftriaxone and cefotaxime, with or without clavulanic acid, to 
detect the production of ESBLs. Results are usually available 
within 6 hours. 
In a study,4 the test sensitivities for MicroScan ESBL plus 
ESBL confirmation panel was 100%, VITEK 1 GNS-120 99%, 
Etest ESBL 97% and BD BBL Sensi-Disk ESBL Confirmatory Test 
disks 96%. 
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IV. Other Methods for ESBL Detection 
(i) Cephalosporin/clavulanate combination disks on Iso-
Sensitest agar. The British Society for Antimicrobial 
Chemotherapy has recommended the disk-diffusion method for 
phenotypic confirmation of ESBL presence using ceftazidime/ 
clavulanate and cefotaxime/clavulanate combination disks, 
although recommends that the test be performed with 
semiconfluent growth on Iso-Sensitest agar (rather than confluent 
growth on Mueller-Hinton agar). 
(ii) Double-disk diffusion test. In the late 1980s, French 
investigators13,32 described a disk diffusion test in which synergy 
between cefotaxime and clavulanate was detected by placing a 
disk of amoxicillin/clavulanate (20 µg/10 µg) and a disk of 
cefotaxime (30 µg), 30 mm apart (center to center) on an 
inoculated agar plate. A clear extension of the edge of the 
cefotaxime inhibition zone toward the disk containing clavulanate 
was interpreted as synergy, indicating the presence of an ESBL;  
(iii) Agar supplemented with clavulanate. Ho et al. 31 described 
a method by which Mueller-Hinton agar was supplemented with 4 
µg/ml of clavulanate. Antibiotic disks containing ceftazidime (30 
µg), cefotaxime (30 µg), ceftriaxone (30 µg), and aztreonam (30 
µg) were placed on the clavulanate-containing agar and on regular 
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clavulanate free Mueller-Hinton agar plates. A difference in β-
lactam zone width of 10 mm on the two media was considered 
positive for ESBL production. 
(iv) Disk replacement method. Casals and Pringler 
(Mediterranean Congress of Chemotherapy, Barcelona, Spain, 20 
to 25 May 1990) described the following method. Three amoxicillin/ 
clavulanate disks are applied to a Mueller-Hinton plate inoculated 
with the test organism. After 1 hour at room temperature, these 
antibiotic disks are removed and replaced on the same spot by 
disks containing cefotaxime, ceftazidime and aztreonam. Control 
disks of these three antibiotics are simultaneously placed at least 
30 mm from these locations. A positive test is indicated by a zone 
increase of 5 mm for the disks which have replaced the 
amoxicillin/clavulanate disks compared to the control disks.  
 
(v) Three-dimensional test. The three-dimensional test gives 
phenotypic evidence of ESBL-induced inactivation of extended- 
spectrum cephalosporins or aztreonam without relying on 
demonstration of inactivation of the β-lactamases by a β-lactamase 
inhibitor. In this test, developed by Thomson, the surface of the 
susceptibility plate is inoculated by standard methods for disk 
diffusion testing, but additionally a circular slit is cut in the agar 
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concentric with the margin of the plate. A heavy inoculum of the 
test organism (109 to 1010 CFU of cells) is pipetted into the slit. β-
Lactam-impregnated disks are then placed on the surface of the 
agar 3 mm outside of the inoculated circular slit. β-Lactamase-
induced inactivation of each test antibiotic is detected by 
inspection of the margin of the zone of inhibition in the vicinity of its 
intersection with the circular three-dimensional inoculation. The 
presence of β-lactamase-induced drug inactivation is visualized as 
a distortion or discontinuity in the usually circular inhibition zone or 
the production of discrete colonies in the vicinity of the inoculated 
slit. 
 
 
 
 
 
 
 
 
(vi) Molecular ESBL detection techniques48 
Test Advantages Disadvantages 
DNA 
probes 
Specific for gene 
family (e.g., TEM or 
Labor intensive, cannot 
distinguish between ESBLs and 
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SHV) non-ESBLs, cannot distinguish 
between variants of TEM or 
SHV 
PCR Easy to perform, 
specific for gene 
family (e.g.,TEM or 
SHV) 
Cannot distinguish between 
ESBLs and non-ESBLs, cannot 
distinguish between variants of 
TEM or SHV 
Oligotypin
g 
Detects specific 
TEM variants 
Requires specific 
oligonucleotide probes, labor 
intensive, cannot detect new 
variants 
PCR-
RFLP 
Easy to perform, 
can detect specific 
nucleotide changes
Nucleotide changes must result 
in altered restriction site for 
detection 
PCR-
SSCP 
Can distinguish 
between a number 
of SHV variants 
Requires special 
electrophoresis conditions 
LCR Can distinguish 
between a number 
of SHV variants 
Requires a large number of 
oligonucleotide primers 
Nucleotide 
sequencin
g 
The gold standard, 
can detect all 
variants 
Labor intensive, can be 
technically challenging, can be 
difficult to interpret manual 
methods 
 
 
TREATMENT AND OUTCOME OF INFECTIONS WITH ESBL-
PRODUCING ORGANISMS 
In Vitro Studies 
Given the ability of ESBL-producing organisms to hydrolyze many 
β-lactam antibiotics, it is not surprising that antibiotic choice for 
infections with such organisms is seriously reduced.  
Antibiotic Choice for Serious Infections: 
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Recommended Treatment for Infections with ESBL 
producers18 
S.N
o 
Infection Type Therapy of 
choice 
Second-Line Therapy 
1. Urinary tract 
Infection 
Quinolone* Amoxycillin/Clavulanate 
2. Bacteremia Carbapene
m 
Quinolone* 
3. Hospital 
acquired 
pneumonia 
Carbapene
m 
Quinolone* 
4. Intra-abdominal 
infection 
Carbapene
m 
Quinolone*(plus 
Metronidazole) 
5. Meningitis Meropenem Intrathecal Polymyxin B 
* If the organism is susceptible 
 
Third-generation cephalosporins are poor choices for the treatment 
of serious infections due to ESBL producing organisms. Failure 
rates are high when MICs of the cephalosporins are elevated (for 
example, 4 or 8 µg/ml) but still within the susceptible range. 
Cefepime should not be used as first-line therapy against ESBL-
producing organisms; if it is used (for example, against organisms 
with a cefepime MIC of 2 µg/ ml), it should be used in high dosage 
(at least 2 g twice a day). In vitro synergy may be achievable 
between cefepime and amikacin.  
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Carbapenems should be regarded as the drugs of choice for 
serious infections with ESBL-producing organisms. In nosocomial 
meningitis, meropenem should be regarded as the drug of choice.  
 
 
 
 
 
MATERIALS & METHODS 
The present bacteriological study was carried out on samples collected 
from patients admitted in the hospital as Inpatients and also patients attending 
the Outpatient Department of Government Stanley Hospital, from June, 2006 
to May, 2007. 
A total of 204 klebsiella were isolated from 1700 specimen collected 
and processed in the Department of Microbiology, Stanley Medical College, 
Chennai and were included in this study. 
 
Criteria for selection of ESBL producing Klebsiella: Routine 
disk diffusion susceptibility testing was performed by modified 
Kirby bauer method following the criteria put forward by the CLSI, 
with 30 µg of 3rd generation Cephalosporins. Isolates found 
resistant to these drugs were selected for the presence of ESBL. 
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Materials : 
Isolates obtained from various clinical samples like urine, pus, 
sputum and blood were analysed for ESBL production. 
 
Methods: 
The methodology includes – 
1. Collection of specimen 
2. Specimen Processing 
3. Identification of the pathogen 
4. Antimicrobial sensitivity testing 
5. Initial Screening test 
6. Phenotypic Confirmatory test 
7. Double disk diffusion test (DDST) 
8. Minimum Inhibitory Concentration (MIC) Determination 
9. CLSI 2006 Protocol 
10. Polymerase Chain Reaction (PCR) for detection of 
ESBL producing genes 
 
1. Collection of specimen: 
Urine: Urine samples were collected, by sampling the 
midstream flow, following the Clean-Catch technique. The 
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purpose was to collect the urine that has been sitting in the 
bladder, discarding the initial portion that has been in contact 
with the urethra and presumably contaminated with urethral 
flora.37 In paedriatic patients, urine flow was stimulated by 
tapping just above the pubis with two fingers one hour after the 
feed; one tap/second was given for one minute, an interval of 
one minute was allowed, then tapping was resumed in this 
cycle.41 
In case of an indwelling catheter, the catheter collection port 
was disinfected with 70% ethanol, and 5 to 10 ml of urine was 
aspirated with needle and syringe. 
The collected specimen was transported to the lab within 2 
hours, and in case of delay in processing, was kept at 4˚C for a 
maximum of 24 hours.9 
 
Pus:  The wound area was wiped with sterile saline, and the 
swab was rolled along the leading edge of the wound. The 
collected specimen was transported to the lab within 2 hours, 
and in case of delay in processing, were kept at 4˚C for a 
maximum of 24 hours.9 
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Body fluids: The skin was disinfected before aspirating the 
sample, and needle aspiration was done. The sample was 
transported at room temperature and processed without delay. 
 
Sputum: The patient was advised to rinse or gargle with water 
before collection, and specimen collected from a deep cough. 
 
Blood: Sampling of blood was done before starting antibiotics, 
and during febrile episodes. If the patient was already on 
antibiotics, then blood was drawn just before the next dose of 
drug. The venipuncture site was cleaned with 1% iodine and 
allowed to dry for 1 – 2 minutes and then the area was wiped 
with a 70% alcohol wash and allowed to dry. Blood was drawn 
upto 10 ml in adults and 5 ml in children, aseptically using a 
syringe and needle. Without removing the needle, blood was 
transferred to a Brain-Heart Infusion broth containing bottle 
containing 50 ml of media, giving an overall dilution of 1:5 to 
1:10. The bottle was incubated at 37˚ C.41 
 
 
2. Specimen Processing: 
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Once the specimen was received in the laboratory, it was 
cultured onto Blood agar plate and MacConkey agar plate and 
incubated aerobically at 37˚ C for 18 to 24 hours. 
3. Identification of the pathogen: 
 Non-motile Short stout gram negative bacilli on gram staining, 
and large, non-hemolytic, greyish white mucoid colonies on 
Blood agar plate and pink colored lactose fermenting mucoid 
colonies in MacConkey agar plate suggests Klebsiella species. 
Biochemical reactions for their identification were as follows: 
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A/A  
G+ P N P 
Utilize
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A/A – Acid slant / Acid butt, G+ – Gas produced,  
P – Positive, N – Negative    
MR – Methyl Red, VP – Voges-Proskauer 
 
4. Antimicrobial sensitivity testing: 
Routine disk susceptibility testing of the Klebsiella isolates were 
performed by modified Kirby-Bauer Method in Muller Hinton 
agar medium obtained from Himedia. The results are affected 
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by the thickness of the medium and the inoculum density.5 To 
overcome excessive thickness, in a plate of 90 mm diameter, 
14 ml of medium was poured, to obtain a thickness of 4mm of 
media.  
Preparation of Inoculum (Growth Method): 37 
1. The inoculum was prepared by touching with a wire loop the 
tops of four or five similar appearing, well isolated colonies 
on an agar plate culture, and inoculated onto 4 to 5 ml of 
nutrient broth.  
2. The culture was incubated at 35˚ C until it matched in density 
with 0.5 McFarland’s standard, which corresponds to 150 
million organisms/ml.  
3. Within fifteen minutes after adjusting the turbidity of the 
inoculum, a sterile nontoxic cotton swab was dipped into the 
inoculum suspension and the swab rotated several times 
with firm pressure on the inside wall of the tube to remove 
excess fluid.  
4. The dried surface of a Mueller-Hinton agar plate that has 
been brought to room temperature is inoculated by streaking 
the swab three times over the entire agar surface, rotating 
the plate approximately 60˚ each time to ensure an even 
distribution of the inoculum. Finally, the rim of the agar was 
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swabbed, and the lid of the dish was replaced. Atleast 3 to 5 
minutes was allowed but not longer than 15 minutes, for the 
surface of the agar to dry before placing the antibiotic discs. 
Testing of antibiotics: 
1. Appropriate antimicrobial-impregnated discs of 6mm 
diameter obtained from HiMedia were placed on the surface 
of the agar, using forceps. 
2. Each disc was gently tamped down on to the agar to provide 
uniform contact. A disc once it has contacted the agar was 
not moved, because some of the drug diffuses almost 
immediately. Discs were evenly distributed on the agar so 
that they are not closer to each other. 
3. The plates were inverted and placed in a 35˚ C air incubator 
for 16 – 18 hours  
Interpretation:  
Measurement of zone diameters: The plates after overnight 
incubation were examined. With the use of sliding calipers, a 
ruler or a template, the zones of complete growth inhibition 
around each of the discs were carefully measured to within the 
nearest millimeter. The diameter of the disc was included in this 
measurement. 
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All measurements were made with the unaided eye, while 
viewing the back of the Petri dish with reflected light against a 
black, non-reflecting back ground. The plates were viewed from 
a directly vertical line of sight to avoid any parallax that may 
result in misreading. 
General precautions: 
• Working stock of antibiotic discs were stored in sealed 
containers with a dessicant at less than 8˚ C, and brought 
to room temperature slowly to minimize condensation of 
moisture, which may lead to hydrolysis of the antibiotic. 
• Care was taken not to leave the inoculated plates at room 
temperature before and after placing the discs. 
• Plates were incubated not stacked more than three high.41 
 
5. Initial Screening test: The sensitivity of the isolates to Third 
Generation Cephalosporins ceftazidime, and cefotaxime, each 
30 µg/disc and to the other antibiotics such as ampicillin (10 
µg), amoxicillin (10 µg), co-trimoxazole (1.25/23.75 µg), 
gentamicin (10 µg), amikacin (30 µg), Ciprofloxacin (5 µg) and 
imipenem (10 µg), (Hi-Media, India) was determined by the disc 
diffusion method.The results were interpreted as per Clinical 
Laboratory Standards Institute (CLSI) 
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recommendations.17 Escherichia coli ATCC 25922 strain was 
used for quality control. Isolates with resistance or with 
decreased susceptibility (intermediate by CLSI criteria) to any of 
the Third Generation Cephalosporins were selected for further 
study.  
Sl. 
No. 
Drug Disk 
Content 
µg 
Resistant
mm or 
less 
Intermediate 
mm 
Sensitive
mm or 
more 
1 Ampicillin 10  13 14-16 17 
2 Amoxycillin 10 14 15-16 17 
3 Co-trimoxazole 1.25+23.75 10 11-15 16 
4 Gentamycin 10 12 13-14 15 
5 Amikacin 30 14 15-16 17 
6 Ciprofloxacin 5 15 16-20 21 
7 Cefotaxime 30 14 15-22 23 
8 Ceftazidime 30 14 15-17 18 
9 Imipenem 10 < 13 14-15 > 16 
 
 
6. Phenotypic Confirmatory test17,39: Antibiotic sensitivity testing 
was done on Mueller Hinton agar with 0.5 McFarland’s standard of 
the organism42. The drugs used were Cefotaxime and Ceftazidime 
each 30 µg alone and in combination with Clavulanic acid 10 µg. 
Organisms with 5 mm increase in zone of inhibition with drug and 
Clavulanic acid, were confirmed as ESBLs. 
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7. Double Disc Diffusion Synergy Test (DDST)59: In the DDST, 
synergy was determined between a disc of augmentin (20 mg 
amoxycillin and 10 mg clavulanic acid) and a 30 mg disc of Third 
Generation Cephalosporin test antibiotic placed at a distance of 30 
mm apart on a lawn culture of the resistant isolate under test on 
Mueller-Hinton Agar (MHA, Hi-Media). The test organism was 
considered to produce ESBL, if the zone size around the test 
antibiotic disc increased towards the augmentin disc. This increase 
occurs because the clavulanic acid present in the augmentin disc 
inactivates the ESBL produced by the test organism 
 
8. Minimum Inhibitory Concentration (MIC) determination: 
Done by agar dilution method: Muller Hinton agar was prepared in 
tubes and autoclaved.  It is then allowed to cool in a 50oC water 
bath. Serial dilution of the 3 GCs ceftazidime and cefotaxime were 
prepared in sterile distilled water to give a final concentration 
ranging from 2µg – 2048µg/ml of agar. 
After adding the drugs to the medium at 50o C it was mixed 
well and poured into sterile Petri dishes. (The media was used 
immediately otherwise potency of drugs will be affected.  We can 
inoculate upto 12 different organisms in a single plate). 
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A control plate containing the test medium without the 
antibiotic was prepared for each series of test. 
Plates of various concentrations were divided into required 
number (9-12 divisions / plate) 0.003 ml of inoculum was put into 
the appropriate quadrant and incubated at 37oC for 16-20 hrs. 
Minimum inhibitory concentration was the lowest 
concentration at which no visible growth occurs. 
Isolates were tested for various concentrations of 
cephalosporin combined with 2µg/ml of clavulanic acid from 0.5µg 
to 2048µg / ml of agar and the MIC determined. 
 
 
 
 
 
 
 
 
 
 
 
9. CLSI 2006 Protocol16: 
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According to CLSI guidelines 2006, 
 Initial Screening 
Test 
(In Mueller Hinton 
Agar) 
Phenotypic Confirmatory 
Test 
(In Mueller Hinton Agar) 
Antimicrobial 
Disc 
Concentration 
Ceftazidime 30 µg 
Cefotaxime 30 µg 
Ceftazidime 30 µg and 
Ceftazidime / Clavulanic acid 
30/10 µg 
& 
Cefotaxime 30 µg and 
Cefotaxime / Clavulanic acid 
30/10 µg 
(Confirmatory test requires all 
the four tests) 
Results Ceftazidime ≤22mm 
Cefotaxime ≤27mm 
≥ 5mm increase in zone 
diameter with and without 
Clavulanic acid. 
Quality 
Control 
Klebsiella pneumoniae ATCC 700603 
Escherichia coli ATCC 25922 
Expected 
zone size 
Klebsiella pneumoniae ATCC 700603 – 
Ceftazidime : 10 – 18 mm 
Cefotaxime : 17 – 25 mm 
≥ 5mm increase in zone for Ceftazidime with and 
without Clavulanic acid 
≥ 3mm increase in zone for Cefotaxime with and 
without Clavulanic acid 
Escherichia coli ATCC 25922 – 
≤ 2mm increase in zone with and without Clavulanic 
acid 
 
Along with ESBL confirmatory tests, ATCC Klebsiella 
and ATCC Escherichia coli were done. 
 
 
 
10. POLYMERASE CHAIN REACTION FOR DETECTION OF 
ESBL PRODUCING GENES 
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(a) Identification of SHV, CTX-M-3 and CTX-M-14 
GENES 
1. DNA Extraction45,46 was done by alcohol extraction 
method from young broth culture of the organisms. 
 
2 .Polymerase Chain Reaction  
PCR was carried out in a Peltier Thermal cycler (PTC 200) 
MJ Research PCR which had an initial denaturation for about 5 
minutes at 94 oC.  Each cycle had a 2nd denaturation for about 1 
minute. 
Annealing at 58 o C was done for 1 minute. 
Thirty five cycles were performed and a final extension was 
done for 10 minutes at 72 o C 
3. Gel Documentation:  
After the reaction, 25 µl. of the amplified samples were run on a 1.5 % 
agarose gel and electrophoresis done at 50 V with 1 x Tris Acetate EDTA 
buffer.  Amplicons were visualized using Ethidium bromide staining and 
scored using 100 bp DNA ladder as reference. 
Gels were viewed in a U - V gel documentation Unit and 
Photographed. 
 
4. Primer Sequences used: 
 
CTX-M3F  5’ AATCACTGCGCCAGTTCACGCT 3’ 
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CTX-M3R  5’ GAACGTTTCGTCTCCCAGCTGT 3’ 
 
CTX-M14F  5’ TACCGCAGATAATACGCAGGTG 3’ 
 
CTX-M14R  5’ CAGCGTAGGTTCAGTGCGATCC 3’ 
 
SHV-F  5’ AACGGAACTGAATGAGGCGCT 3’ 
 
SHV-R  5’ TCCACCATCCACTGCAGCAGCT 3’ 
 
 
 
RESULTS 
 Klebsiella isolates obtained from various clinical samples in 
the Department of Microbiology, Government Stanley Hospital 
were studied from June, 2006 to May, 2007 to find out the 
incidence of Extended Spectrum Beta Lactamases (ESBL) 
producers among them. Study included patients of both sexes and 
of all age groups. The Specimen included were Urine, Sputum, 
wound swab and Blood. 
Out of the 204 Klebsiella isolates obtained, 111 were 
Klebsiella pneumoniae and 93 were Klebsiella oxytoca. 121 
isolates out of 204 were positive for Extended Spectrum Beta 
Lactamase production and 83 were found to be negative for 
enzyme production. 
The Results were analyzed as follows. 
- 69 - 
 
Table 1: Total ESBL klebsiella isolates 
Number of 
Isolates 
ESBL 
Klebsiella 
Non-ESBL 
Klebsiella 
204 121 (59.31%) 83 (40.69%) 
 
Total number of Klebsiella isolates taken for study were 
204, of which 121 (59.31%) were positive for Extended 
spectrum Beta lactamase production and 83 (40.69%) 
isolates were found to be negative. 
 
 
 
Table 2: Age And Sex Distribution Of Klebsiella 
Isolates ( n = 204) 
Age Male Female Total 
< 20 22 43 65 
20-30 13 13 26 
31-40 17 7 24 
41-50 14 28 42 
> 50 27 20 47 
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TOTAL 93 (45.59 %) 111 (54.41 %) 204 
 
Total numbers of isolates taken for study were 204, which included total of 
93 males (45.59 %) and 111 females (54.41 %). Among them, 22 males 
and 43 females were less than 20 years, between 20-30 years of age 
there were 13 males and 13 females, between 31-40 years 17 males and 
7 females, between 41-50 years there were 14 males and 28 females and 
over 50 years there were 27 males and 20 females. 
 
Table 3: ESBL positive & negative Klebsiella in different 
specimen (n=204) 
Specimen Total ESBL Positive ESBL Negative 
Urine 97 64 (65.98%) 33 (34.02%) 
Pus 51 27 (52.94%) 24 (47.06%) 
Sputum 37 21 (56.76%) 16 (43.24%) 
Blood 19 9 (47.37%) 10 (52.63%) 
Total 204 121 (59.31%) 83 (40.69%) 
 
Out of the 97 urinary Klebsiella isolates, 64 (65.98 %) were ESBL positive, 
and 33 (34.02 %) were ESBL negative. Of the 51 isolates from Pus 
specimen, 27 (52.94%) were ESBL Positive and 24 (47.06%) were ESBL 
Negative. Among the 37 Sputum isolates, 21 (56.76%) were ESBL 
Positive and 16 (43.24%) were ESBL Negative. And, of the 19 Blood 
isolates, 9 (47.37%) were ESBL Positive and 10 (52.63%) were ESBL 
Negative. 
 
Table 4: ESBL producers among Klebsiella species (n=121) 
 ESBL Positive 
Klebsiella 
pneumoniae
Klebsiella 
oxytoca 
Urine 64 16 (25 %) 48 (75 %) 
Pus 27 18 ( 66.66%) 9 ( 33.34%) 
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Sputum 21 21 (100 %) 0 
Blood 9 9 (100 %) 0 
Total 121 64 ( 52.9%) 57 (47.1 %) 
 
Out of the 64 urinary ESBL positive Klebsiella isolates, 16 (25 %) were 
Klebsiella pneumoniae, and 48 (75 %) were Klebsiella oxytoca. Of the 27 
isolates from Pus specimen, 18 (66.66 %) were Klebsiella pneumoniae 
and 9 (33.34 %) were Klebsiella oxytoca. Among the 21 Sputum isolates, 
all 21 (100 %) were Klebsiella pneumoniae. And, of the 9 Blood isolates, 
all 9 (100 %) were Klebsiella pneumoniae. 
 
Table 5: Number of Non-ESBL producing Klebsiella species (n=83) 
 ESBL Negative 
Klebsiella 
pneumoniae
Klebsiella 
oxytoca 
Urine 33 4 (12.12 %) 29 (87.88 %) 
Pus 24 19 (79.16 %) 5 (20.84%) 
Sputum 16 14 (87.5 %) 2 (12.5 %) 
Blood 10 10 (100 %) 0 
Total 83 47 36 
 
Out of the 33 urinary ESBL positive Klebsiella isolates, 4 (12.12 %) were 
Klebsiella pneumoniae, and 29 (87.88 %) were Klebsiella oxytoca. Of the 
24 isolates from Pus specimen, 19 (79.16 %) were Klebsiella pneumoniae 
and 5 (20.84 %) were Klebsiella oxytoca. Among the 16 Sputum isolates, 
14 (87.5 %) were Klebsiella pneumoniae and 2 (12.5 %) were Klebsiella 
oxytoca. And, of the 10 Blood isolates, all 10 (100 %) were Klebsiella 
pneumoniae. 
 
Table 6: Sex-wise breakup of ESBL Klebsiella species (n=204) 
 ESBL Non-ESBL Total 
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Male 56 (60.22 %) 37 (39.78 %) 93 
Female 65 (58.56 %) 46 (41.44 %) 111 
Total 121 83 204 
 
Out of the 93 Klebsiella isolates from male patients, 56 
(60.22 %) were ESBL positive Klebsiella, and 37 (39.78 %) were 
ESBL negative. Out of the 111 Klebsiella isolates from female 
patients, 65 (58.56 %) were ESBL positive Klebsiella, and 46 
(41.44 %) were ESBL negative. 
 
Table 7: Number of ESBL producing Klebsiella species in 
OP/IP (n=121) 
 ESBL Non-ESBL Total 
OP 28 (70 %) 12 (30 %) 40 
IP 93 (56.7 %) 71 (43.3 %) 164 
Total 121 83 204 
 
Out of the 40 Klebsiella isolates from Outpatient department, 
28 (70 %) were ESBL positive Klebsiella, and 12 (30 %) were 
ESBL negative. Out of the 164 Klebsiella isolates from Inpatients, 
93 (56.7 %) were ESBL positive Klebsiella, and 71 (43.3 %) were 
ESBL negative. 
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Table 8: ESBL positive Klebsiella species by different 
methods (n=121) 
 
Methods DDST MIC Meropenem sensitivity 
Positive 
Isolates 
121 
(100%) 
121 
(100%) 121 (100%) 
 
All 121 Klebsiella species found ESBL positive by screening 
method were subjected to further tests, and by all methods they 
were confirmed as ESBL positive. 
 
Table 9: Antibiotic Sensitivity pattern of ESBL producing 
Klebsiella (n=121) 
ANTIBIOTIC Sensitive ESBL Klebsiella 
Ampicillin 0 
Amoxicillin 0 
Cotrimoxazole 0 
Gentamycin 9 (7.44 %) 
Amikacin 66 (54.54 %) 
Ciprofloxacin 20 (16.53 %) 
Cefotaxime 0 
Ceftazidime 6 (4.96 %) 
Imipenem 121 (100 %) 
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Out of the 121 ESBL positive Klebsiella isolates, none were 
sensitive to Cotrimoxazole, 9 (7.44 %) were sensitive to Gentamycin, 
66 (54.54 %) were sensitive to Amikacin, 20 (16.53 %) were sensitive 
to Ciprofloxacin and all were sensitive to Imipenem. 
 
 
 
 
 
 
 
 
 
Table 10: Antibiotic Sensitivity of ESBL Klebsiella pneumoniae 
(n=64) 
ANTIBIOTIC Klebsiella pneumoniae 
Ampicillin 0 
Amoxicillin 0 
Cotrimoxazole 0 
Gentamycin 3(4.69 %) 
Amikacin 33(51.56 %) 
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Ciprofloxacin 12(18.75 %) 
Cefotaxime 0 
Ceftazidime 5(7.81%) 
Imipenem 64(100 %) 
 
Of 64 ESBL positive Klebsiella pneumoniae, none were sensitive to Cotrimoxazole, 3 
(4.69 %) were sensitive to Gentamycin, 33 (51.56 %) to Amikacin, 12 (18.75 %) to 
Ciprofloxacin and all were sensitive to Imipenem. 
Table 11: Antibiotic Sensitivity of ESBL producing Klebsiella 
oxytoca (n=57) 
ESBL Klebsiella oxytoca 
Ampicillin 0 
Amoxicillin 0 
Cotrimoxazole 0 
Gentamycin 6(10.53 %) 
Amikacin 33(57.89 %) 
Ciprofloxacin 8(14.04) 
Cefotaxime 0 
Ceftazidime 1(1.75 %) 
Imipenem 57(100 %) 
Out of the 57 ESBL positive Klebsiella oxytoca, none were 
sensitive to Cotrimoxazole, 6 (10.53 %) were sensitive to 
Gentamycin, 33 (57.89 %) were sensitive to Amikacin, 8 (14.04 %) 
were sensitive to Ciprofloxacin and all were sensitive to Imipenem. 
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Table 12: Antibiotic Sensitivity pattern of ESBL negative 
Klebsiella (n = 83) 
ANTIBIOTIC Non-ESBL Klebsiella 
Ampicillin 31 (37.35 %) 
Amoxicillin 28 (33.73 %) 
Cotrimoxazole 39 (46.99 %) 
Gentamycin 68 (81.93 %) 
Amikacin 83 (100 %) 
Ciprofloxacin 78 (93.98 %) 
Cefotaxime 83 (100 %) 
Ceftazidime 83 (100 %) 
Imipenem 83 (100 %) 
 
Out of the 83 ESBL negative Klebsiella isolates, 31 (37.35 
%) were sensitive to ampicillin, 28 (33.73 %) were sensitive to 
amoxicillin, 39 (46.99 %) were sensitive to Cotrimoxazole, 68 
(81.93 %) were sensitive to Gentamycin, 78 (93.98 %) were 
sensitive to Ciprofloxacin and all were sensitive to amikacin, 
Cefotaxime, Ceftazidime and Imipenem. 
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Table 13: Antibiotic Sensitivity of ESBL negative Klebsiella 
pneumoniae (n=47) 
ANTIBIOTIC Klebsiella pneumoniae 
Ampicillin 21 (44.68%) 
Amoxicillin 18 (38.30%) 
Cotrimoxazole 18 (38.30%) 
Gentamycin 40 (85.11%) 
Amikacin 47 (100%) 
Ciprofloxacin 45 (95.74%) 
Cefotaxime 47 (100%) 
Ceftazidime 47 (100%) 
Imipenem 47 (100%) 
 
Out of the 47 ESBL negative Klebsiella pneumaoniae, 21 
(44.68 %) were sensitive to ampicillin, 18 (38.30 %) were sensitive to 
amoxicillin and Cotrimoxazole, 40 (85.11 %) were sensitive to 
Gentamycin, 45 (95.74 %) were sensitive to Ciprofloxacin and all were 
sensitive to amikacin, Cefotaxime, Ceftazidime and Imipenem. 
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Table 14: Antibiotic Sensitivity of ESBL negative Klebsiella 
oxytoca (n=36) 
ESBL Klebsiella oxytoca 
Ampicillin 10 (27.78 %) 
Amoxicillin 10 (27.78 %) 
Cotrimoxazole 21 (58.33 %) 
Gentamycin 28 (77.78 %) 
Amikacin 36 (100 %) 
Ciprofloxacin 33 (91.67 %) 
Cefotaxime 36 (100 %) 
Ceftazidime 36 (100 %) 
Imipenem 36 (100 %) 
 
Out of the 36 ESBL negative Klebsiella oxytoca, 10 (27.78 
%) were sensitive to ampicillin and amoxicillin, 21 (58.33 %) were 
sensitive to Cotrimoxazole, 28 (77.78 %) were sensitive to 
Gentamycin, 33 (91.67 %) were sensitive to Ciprofloxacin and all 
were sensitive to amikacin, Cefotaxime, Ceftazidime and 
Imipenem. 
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Table 15: Minimum Inhibitory Concentration (MIC) of ESBL 
Klebsiella to Cefotaxime (n=121) 
Concentration of Cefotaxime in Agar (µg/ml)  
Total 2 4 8 16 32 64 128 256 512 1024 2048
Klebsiella 
pneumonia
e 
64 0 0 0 0 0 3 21 32 46 60 64 
Klebsiella 
oxytoca 57 0 0 0 0 0 0 19 26 35 51 57 
 
Minimum inhibitory concentration of Cefotaxime for the ESBL 
producing organisms in the study was between 64 µg/ml of agar to 2048 
µg/ml of agar. 
 
Table 16: Minimum Inhibitory Concentration (MIC) of ESBL 
Klebsiella to Cefotaxime with 2µg/ml Clavulanate (n=121) 
Concentration of Cefotaxime with 
2µg/mlClavulanic acid in Agar (µg/ml)  
 
Total 0.5 1 2 4 8 16 32 64 128
Klebsiella 
pneumonia
e 
64 3 27 43 48 52 60 63 64 64 
Klebsiella 
oxytoca 57 2 18 39 45 48 51 53 57 57 
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Minimum inhibitory concentration of Cefotaxime for the ESBL 
producing organisms in the study was between 0.5 µg/ml of agar to 64 µg/ml 
of agar in the presence of clavulanic acid at a concentration of 2 µg/ml of agar 
showing 8 fold reductions in MIC. 
 
Table 17: Minimum Inhibitory Concentration (MIC) of ESBL 
Klebsiella to Ceftazidime (n=121) 
Concentration of Ceftazidime in Agar (µg/ml)  
Total 2 4 8 16 32 64 128 256 512 1024 2048
Klebsiella 
pneumonia
e 
64 0 0 0 0 0 5 32 43 57 62 64 
Klebsiella 
oxytoca 57 0 0 0 0 0 3 27 38 51 55 57 
Minimum inhibitory concentration of Ceftazidime for the ESBL 
producing organisms in the study was between 64 µg/ml of agar to 2048 
µg/ml of agar  
 
Table 18: Minimum Inhibitory Concentration (MIC) of ESBL 
Klebsiella to Ceftazidime with 2µg/ml Clavulanate (n=121) 
Concentration of Ceftazidime with 2µg/mlClavulanic 
acid in Agar (µg/ml) 
 
Total 0.5 1 2 4 8 16 32 64 128
Klebsiella 
pneumonia
e 
64 23 57 60 64 64 64 64 64 64 
Klebsiella 
oxytoca 57 17 56 56 57 57 57 57 57 57 
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 Minimum inhibitory concentration of Ceftazidime for the ESBL 
producing organisms in the study was between 0.5 µg/ml of agar to 4 µg/ml of 
agar in the presence of clavulanic acid at a concentration of 2 µg/ml of agar 
showing 8 fold reductions in MIC. 
 
Table 19:  PCR Sequencing of ESBL positive Klebsiella (n=30) 
 
 Total SHV CTX-M3 CTX-M14 
Klebsiella 
pneumoniae 15 12 7 3 
Klebsiella oxytoca 15 11 5 0 
 
 PCR for determination of SHV, CTX-M-3, and CTX-M-14 was done. 
SHV gene in 12 Klebsiella pneumoniae and 11 Klebsiella oxytoca 
isolates, CTX-M-3 was found in 7 Klebsiella pneumoniae and 5 Klebsiella 
oxytoca isolates. CTX-M-14 was found in 3 Klebsiella pneumoniae and 
none in any of the Klebsiella oxytoca isolates.  7 Klebsiella pneumoniae 
and 4 Klebsiella oxytoca isolates showed both SHV and CTX-M-3. 
Primer Sequences: 
CTX-M3F  5’ AATCACTGCGCCAGTTCACGCT 3’ 
 
CTX-M3R  5’ GAACGTTTCGTCTCCCAGCTGT 3’ 
 
CTX-M14F  5’ TACCGCAGATAATACGCAGGTG 3’ 
 
CTX-M14R  5’ CAGCGTAGGTTCAGTGCGATCC 3’ 
 
SHV-F  5’ AACGGAACTGAATGAGGCGCT 3’ 
 
SHV-R  5’ TCCACCATCCACTGCAGCAGCT 3’ 
 
- 82 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 The wide spread use of antibiotics in hospitals has led to 
emergence of multidrug resistant organisms of low virulence like 
Klebsiella causing serious opportunistic infections. Over the last 15 
years numerous outbreaks of infection with organisms producing 
extended spectrum β-lactamases (ESBLs) have been observed 
world wide.  
 The advent of ESBL producers has posed a great threat to 
the use of many classes of antibiotics particularly cephalosporins. 
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There are indications that poor outcome occurs when patients with 
serious infections due to ESBL producing organisms are treated 
with antibiotics to which the organism is resistant. 
 ESBL producing Klebsiella pneumoniae were first reported in 
1983 from Germany and since then a steady increase in 
resistance against cephalosporins has been seen. ESBLs are 
encoded by transferable conjugative plasmids, which also quite 
often code resistant determinants to other antibiotics. An ESBL 
variant may be selected de novo in a given hospital or it may be 
introduced from another centre. Its further spread within the 
hospital can be consequence of plasmid transmission. Persistence 
and outbreaks of ESBL producers have been convincingly 
correlated with extensive use of cephalosporins. 
 Klebsiella pneumoniae is an important cause of nosocomial 
infection and infections due to ESBL producers are of concern as 
third generation cephalosporins (3GC) are commonly used for 
treatment of infections due to gram-negative organisms. These 
infections are difficult to control as they are usually associated with 
resistance to aminoglycosides. 
 The clinical microbiology laboratory has the task of screening 
and confirming isolates for ESBL production. This is a challenge 
for the laboratory to detect ESBL-containing gram negative bacilli 
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because they can appear susceptible in vitro to certain beta-lactam 
antimicrobial agents yet result in clinical treatment failure. 
 The prevalence of ESBLs among Clinical Isolates varies 
greatly worldwide and in geographic areas and is rapidly changing 
over time.  
 In the present study, the occurrence of ESBL producing 
Klebsiella species were 121 (59.31 %), correlating with Indian 
studies like 56 % obtained by Amita Jain et al3, 58 % by Bithika 
Duttaroy et al12, 58 % by Gunseren et al29 and 53 % by Revathi et 
al53. Values higher than our study were obtained in studies like the 
72% positive by Shukla et al54, 73% positive by Singhal et al55, 80 
% positive reported by Purva et al52, 86 % reported by Prabha et 
al51 and 87 % reported by Subha et al5 . 
But, the percentage of ESBLs were significantly higher than 
European and US studies which gave 21 % Fluit et al21, Albertini et 
al2, 23 % Meifang et al44 and 29 % Jacoby et al24, and Indian 
studies like 8.5% by Rodrigues et al14, 21% by Menon et al45 and 
14% by Kumar et al38. 
               The Male: Female ratio of Klebsiella samples analyzed 
was 93:111 (1:1.2).  
              Of the 97 urinary isolates of Klebsiella, 64 (65.98 %) were 
ESBL positive and from 51 Pus specimen 27 (52.94 %) were 
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ESBL positive. Likewise, 21 (56.76 %) from 37 Sputum specimen 
and 9 (47.37 %) from blood specimen were ESBL positive. 
 In the study by Bithika Duttaroy et al12, 36 % in Urine 
specimen, 27.7 % in Pus, 18.2 % in Blood and 15.1 % in others 
were ESBL positive. 
                In a study by Purva et al52, 58 % in Urine specimen, 52 
% in Pus, 87 % in Blood and 74 % in others were ESBL positive 
In the present study, among the 121 ESBL positive Klebsiella, 64 
(52.9 %) of Klebsiella pneumoniae and 57 (47.1 %) of Klebsiella oxytoca 
were obtained. 
In a study by Maurizio et al43, ESBL positive Klebsiella 
pneumoniae obtained were 74.7 % and ESBL positive Klebsiella oxytoca 
were 77.78 %. Coudron et al49 obtained 37 % ESBL Klebsiella 
pneumoniae and 4 % ESBL positive Klebsiella oxytoca. As per the study 
of Luzzaro et al22, 20 % Klebsiella pneumoniae isolates and 15.1 % of 
Klebsiella oxytoca were ESBL positive 
In present study, out of the 64 urinary ESBL positive Klebsiella 
isolates, 16 (25 %) were Klebsiella pneumoniae, and 48 (75 %) were 
Klebsiella oxytoca. In a study by Bithika et al12, of the total Klebsiella 
isolated from urine, 36 % were ESBL positive. 
 Of the 27 isolates from Pus specimen, 18 (66.66 %) were 
Klebsiella pneumoniae and 9 (33.34 %) were Klebsiella oxytoca. In a study 
by Kanungo et al7, 43.75 % and 27.7 % by Bithika et al12 of ESBL positive 
Klebsiella pneumoniae were obtained. 
Among the 21 Sputum isolates, all 21 (100 %) were Klebsiella 
pneumoniae. In a study by Bithika et al12, 15.1 % Klebsiella pneumoniae 
isolates were ESBL positive. 
And, of the 9 Blood isolates, all 9 (100 %) were Klebsiella 
pneumoniae. In a study by Bithika et al12, 18.2 % Klebsiella pneumoniae 
isolates were ESBL positive.  
In our study, out of the 121 ESBL positive Klebsiella isolates, none 
were sensitive to Cotrimoxazole, 9 (7.44 %) were sensitive to Gentamycin, 66 
(54.54 %) were sensitive to Amikacin, 20 (16.53 %) were sensitive to 
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Ciprofloxacin and all were sensitive to Imipenem, correlating with Hansotia et 
al30. 
And among the 83 ESBL negative Klebsiella isolates, 31 
(37.35 %) were sensitive to ampicillin, 28 (33.73 %) were sensitive 
to amoxicillin, 39 (46.99 %) were sensitive to Cotrimoxazole, 68 
(81.93 %) were sensitive to Gentamycin, 78 (93.98 %) were 
sensitive to Ciprofloxacin and all were sensitive to amikacin, 
Cefotaxime, Ceftazidime and Imipenem. 
In a study by Baby Padmini et al8, among ESBL producers, 
86% were susceptible to amikacin, 25 % to gentamicin, 26 % to 
cotrimoxazole and 9 % to ciprofloxacin. And, among non-ESBL 
producers, 94 % were susceptible to amikacin, 92 % to 
gentamicin, 47 % to cotrimoxazole and 64 % to ciprofloxacin. 
According to Amita et al3, among ESBL producers, 41.4 % 
were susceptible to amikacin, 29.3 % to gentamicin, 31 % to 
cotrimoxazole and 32.8 % to ciprofloxacin. And, among non-ESBL 
producers, 81 % were susceptible to amikacin, 47.6 % to 
gentamicin, 38 % to cotrimoxazole and 81 % to ciprofloxacin. 
Luzzaro et al22 study gives a susceptibility of 51.9 % for 
amikacin, 43.2 % for Gentamicin and 56.8 % for Ciprofloxacin, in 
ESBL Klebsiella pneumoniae, and a susceptibility of 100 % for 
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amikacin, 72.2 % for Gentamicin and 72.2 % for Ciprofloxacin, in 
ESBL Klebsiella oxytoca. 
In our study, out of the 121 ESBL positive Klebsiella isolates, (16.53 
%) were sensitive to Ciprofloxacin, and among the 83 ESBL negative 
Klebsiella isolates, 78 (93.98 %) were sensitive to Ciprofloxacin. This 
correlates well with the study of Patterson et al19, giving a 60 % ESBL 
positives in Ciprofloxacin resistant Klebsiella pneumoniae and 16 % in 
Ciprofloxacin sensitive isolates, thereby, concluding a positive association 
between Ciprofloxacin resistance and ESBL production. 
By agar dilution method, Minimum inhibitory concentration for Cefotaxime 
for the 121 ESBL producing organisms varied from 64 µg/ml to 2048 
µg/ml. This showed MIC 50s at 256 µg/ml and MIC 90s at 1024 µg/ml for 
Klebsiella species. 
In combined with 2 µg/ml. of clavulanic acid, Cefotaxime 
gave a MIC reduced to 0.5 µg/ml - 8 µg/ml. 
MIC for ceftazidime was between 64 µg/ml - 2048 µg/ml, with 
MIC 50s, 512 µg/ml.  
In combination with 2 µg/ml of clavulanic acid, Ceftazidime 
MIC was reduced to 0.5 µg/ml - 8 µg/ml,. From a study by Bithika 
et al12, MIC for third generation cephalosporins was between 2- 
1024 µg/ml and it was reduced to 0.25-128 µg/ml when clavulanic 
acid was added at a concentration of 2 µg/ml. So the present study 
correlates well with the study of Bithika et al12.and Livermore et 
al40. 
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Polymerase Chain Reaction for identification of SHV, CTX – 
M-3 and CTX-M-14 showed presence of SHV genes in 12 of 
Klebsiella pneumoniae and 11 Klebsiella oxytoca isolates, CTX-M-
3 was identified in 7 Klebsiella pneumoniae and 5 Klebsiella 
oxytoca isolate. CTX-M-14 was identified in 3 Klebsiella 
pneumoniae isolates.  
This correlates with the study of Ju-Hsin Chia et al34 from 
Taiwan, where most of the Klebsiella pneumoniae isolates showed 
SHV. SHV was common in studies by Luzzaro et al22, 
Shanmuganathan et al56, Paterson et al20, Miranda et al28 and by 
Zoltan Pragai62. But, in a study by Chanawong et al6, CTX  was 
found to be common. 
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SUMMARY 
Two hundred and four Klebsiella isolates from varied 
specimen provided by patients attending Government Stanley 
Hospital, Chennai, between June, 2006 to May, 2007 formed the 
study group. 
Specimens like urine, blood, wound swabs, sputum and 
blood were cultured and organisms identified by Gram’s staining 
and various biochemical reactions, from a total of 121 isolates, as 
64 (52.9 %) of Klebsiella pneumoniae, and 57 (47.1 %) of 
Klebsiella oxytoca.  
Antibiotic susceptibility testing was done including third generation 
cephalosporins and Klebsiella species found to be resistant to third 
generation cephalosporin were screened for ESBL production by 
phenotypic Confirmatory method, the Double disc synergy test (DDST) 
and by Minimum Inhibitory Concentration technique to be 121 of 204 
specimens. 
ESBL Klebsiella pneumoniae among urine (66 %), pus (53 
%), sputum  (56.7 %) and blood (47.4 %). 
MIC for the isolates was between 64- 2048 µg/ml of agar for 
cefotaxime and ceftazidime alone, which was reduced to 0.5 - 64 
µg/ml and 0.5- 4 µg/ml of agar respectively in the presence of 2 
µg/ml of agar.  
All the 121 isolates (100%) were found to be sensitive to 
imipenem, and 7.44 % to Gentamicin, 54.54 % to Amikacin and 
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16.53 % to Ciprofloxacin, which could be economical alternatives 
to expensive drugs like Imipenem.  
SHV gene, CTX-M-3 and CTX -M-14 were identified in the 
Klebsiella isolates. 
CONCLUSION 
Our study gives 59.3 %, which is intermediate to the varied 
studies in India, but high compared to western countries like in US 
4.2-44.0 per cent, in Canada 15-17 %, and in China 51 %48. In 
India, high prevalence of ESBL producing Klebsiella strains has 
been reported by various groups. Reported frequency of ESBL 
producing Klebsiella spp. from India ranged between 6 and 87 per 
cent3. 
 
 The high percentage of ESBL producing Klebsiella spp may 
be due to the selective pressure imposed by extensive use of 
antimicrobials. The infection control implications of ESBL 
producing Klebsiella spp. are under-recognized.  
 
Our results showed a high incidence of ESBL producing 
Klebsiella species in both In-patient and Outpatient. Routine 
detection of ESBL producing microorganisms is required by 
reliable laboratory methods and since most of these are multidrug 
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resistant, the therapeutic strategies to control infections in the 
hospital setup have to be carefully formulated. 
 
Phenotypic confirmatory method is less worktime and less 
skill demanding while being economical, and will be the ideal 
method for confirmation of ESBL producers. 
A fall in the incidence of ESBL producers, have been noted 
in France in a study after implementing an effective strategy 
against ESBLs were brought in.   Such a workup is imminent for 
our country in the present scenario. 
  
While ESBL producing organisms were 100% sensitive to 
Imipenem, they were also sensitive to cheaper drugs like, 
Gentamicin (7.44 %), Amikacin (54.54 %) and Ciprofloxacin (16.53 
%). Hence if we screen carefully we can minimize the cost of 
treatment for the patients with infections due to ESBL producing 
organisms. 
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APPENDIX 
1. Brain Heart Infusion broth:- 
 
                                                                                            Gm/Liter 
                                  
Calf brain infusion from                                                        
 200  
 
Beef infusion from                                                                 
 250  
 
Proteose peptone                                                                       
10  
 
Dextrose                                                                                      2  
Sodium chloride                                                                          5  
 
Disodium phosphate                                                                 2.50  
 
Add the contents and dissolve by heating. 
 
Adjust the pH to 7.4 + 0.2 
 
Autoclave at 121oC for 15 minutes. 
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2. Peptone Water:- 
 
Peptone                                                                                       10 
g 
 
Sodium chloride, NaCl                                                                5 g 
 
Water                                                                                        1 litre 
 
Dissolve the ingredients in warm water, adjust the pH to 7.4-7.5 
and filter. Distribute as required and autoclave at 121oC for 15 min. 
 
3. MacConkey agar:- 
This is a useful medium for the cultivation of enterobacteria. It 
contains a bile salt to inhibit non-intestinal bacteria and lactose 
with neutral red to distinguish the lactose-fermenting coli forms 
from the lactose –non-fermenting salmonella and shigella groups. 
The concentration of sodium taurocholate may be reduced to suit 
less tolerant organisms. The omission of sodium chloride from the 
medium prevents the spreading of Proteus colonies. 
 
Peptone                                                                                      20 g 
 
Sodium taurocholate, commercial                                                5 g 
 
Water                                                                                        1 litre 
 
Agar                                                                                            20 g 
 
Neutral red solution, 2% in 50% ethanol                                 3.5 ml 
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Lactose, 10% aqueous solution                                             100 ml 
 
 
Dissolve the peptone and taurocholate (bile salt) in the water 
by heating. Add the agar and dissolve it in the steamer or 
autoclave. If necessary, clear by filtration. Adjust the pH to 7.5. 
Add the lactose and the neutral red, which should be well shaken 
before use, and mix. Heat in the autoclave with ‘free steam’ (c. 
100o C) for 1hr., then at 115o C for 15 min. Pour plates. 
 
4. Nutrient agar:- 
                                                                                               Gm/L 
 
Peptic digest of animal tissue                                                  5.00 
 
Beef extract                                                                             1.50 
 
Yeast extract                                                                            5.00 
 
Agar                                                                                       15.00 
 
Dissolve the contents in water and mix by heating Autoclave 
at 121o C for 15 minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml of 
9 cm dia. Petridishes to give 4 mm thickness. 
 
5. Blood agar:- 
 
Sterile sheep blood                                                              50 ml 
 
Peptone                                                                                10 g 
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Beef extract                                                                             3g 
 
Sodium chloride                                                                     5 g 
 
Distilled water                                                                 1000 ml 
 
Autoclave the nutrient agar base at 121o C for 15 minutes 
and blood with sterile precautions and distribute in Petri dishes. 
 
6. Muller Hinton agar:-   
Beef infusion   300  ml 
Casein 
Hydrolysate 
  17 gm
Starch    1.5 gm
Agar  10 gm
Distilled water 1000 ml 
 
Emulsify the starch in a small amount of cold water, pour into 
the beef infusion and add the casein-Hydrolysate and the agar. 
Make up the volume to 1000 ml (1 litre) with distilled water. 
Dissolve the constituents by heating gently at 100o C with 
agitation. 
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 Adjust the pH to 7.4. Dispense in screw-capped bottles and 
sterilize by autoclaving at 121 o C for 20 minutes. 20 to 25 ml of it is 
poured into petridishes of 9 cm diameter to give a thickness of 
4mm. 
 
7. McFarland’s Turbidity Standard for inoculum preparation 
A Barium sulphate 0.5 McFarland standards was prepared 
as follows 
1. A 0.5 ml of 0.048mol/L of Barium chloride was added to 99.5 
ml of 0.18 mol/L of H2SO4 with constant stirring to maintain 
a suspension.  
2. Correct density of the turbidity standard was verified by using 
a spectrophotometer. The absorbance of 625nm should be 
0.08 to0.10 for the 0.5 McFarland standards. 
3. The Barium sulphate suspension was transferred in 4-6 ml to 
a screw capped tube of the same size as those used in 
growing or diluting the bacterial inoculam. 
4. These tubes were tightly sealed and stored in the dark at 
room temperature. 
5. The Barium sulphate turbidity standard was vigorously agitated before 
each use and inspected for a uniform turbid appearance. 
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8. DNA Extraction 
Materials required 
i) Overnight broth culture of the organism 
ii) Lysozyme solution 
iii) Proteinase K 
iv) 10% SDS 
v) 70% ETHANOL 
vi) 95% ETHANOL 
vii) Tris EDTA Buffer 
viii) Sterile eppendorfs & Pipettes 
ix) 3 M sodium acetate 
x) Phenol:  Chloroform 1:1 
Procedure 
 1.5 ml of overnight broth culture was taken in an eppendorf 
tube and centrifuged at 10000 rpm for 4 minutes at 4 o C 
 Supernatant was discarded and pellet was dissolved in 467 
ml. of Tris EDTA buffer. One Ml. of Lysozyme was added to the 
above solution and incubated for 1 hour at 30 o C 
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30 ml. of 10% SDS and 3 ml. of 20 mg./ml  Proteinase 
Kinase K were mixed to the sample and incubated for 1 hour at 37 
o C 
 Equal volume of phenol and chloroform (1:1) mixture was 
added and mixed until the phases were completely mixed. 
Phase lock tubes were centrifuged at 12,000 rpm for 8 minutes to 
pellet the column 
 The solution was pipetted into phase lock   tubes and 
centrifuged at 10000 rpm to purify the DNA. The clear upper layer 
was pipetted into a sterile eppendorf tube. Equal volume of 
chloroform was added and centrifuged at 10,000 rpm for 10 
minutes. 
 The upper aqueous phase was again transferred to a new 
table and to it 1/10th  volume of 3 M sodium acetate solution and 2 
volumes of ice cold absolute alcohol were added and the DNA was 
precipitated. The tubes were again centrifuged at 10,000 rpm for 
15 minutes and the supernatant was discarded. 
Pellet was washed with 70% ethanol by spinning for 5 
minutes at 10,000 rpm. 70% ethanol was discarded on the tissue 
paper and pellet was air dried completely. Extracted DNA was 
suspended in Tris EDTA buffer. 
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9. PCR Master Mix 
 
Milli Q water   12 ml 
10 x buffer   2.5 ml (1x) 
2 mm d NTPs  2.5 ml.  (0.2 m) 
DNA  (50 mg/ml)  1 ml. 
Primer    F   2.5 ml 
    R   2.5 ml 
Taq polymerase ( 2U/ml) 2.0 ml. 
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